$129 Million is the total value of Foresite Capital Management V, LLC's 11 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 35.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| HIMS | Buy | Hims & Hers Health, Inc. | $25,905,265 | +39.8% | 4,041,383 | +21.7% | 20.12% | +41.3% |
| CMPX | Compass Therapeutics, Inc. | $22,132,000 | +120.6% | 4,400,000 | 0.0% | 17.19% | +122.8% | |
| ACRS | Aclaris Therapeutics, Inc. | $19,817,327 | +0.1% | 1,258,243 | 0.0% | 15.39% | +1.1% | |
| Buy | Theseus Pharmaceuticals, Inc. | $17,855,023 | -7.7% | 3,585,346 | +7.5% | 13.87% | -6.8% | |
| Buy | Pardes Biosciences Inc | $16,964,110 | -2.5% | 10,037,935 | +6.8% | 13.18% | -1.5% | |
| Somalogic, Inc. | $8,826,345 | -13.5% | 3,516,472 | 0.0% | 6.86% | -12.6% | ||
| KNTE | Kinnate Biopharma Inc. | $5,337,506 | -49.0% | 875,001 | 0.0% | 4.15% | -48.4% | |
| ACET | Sell | Adicet Bio, Inc. | $4,994,206 | -48.4% | 558,636 | -17.8% | 3.88% | -47.8% |
| New | Disc Medicine, Inc. | $4,843,454 | – | 243,513 | +100.0% | 3.76% | – | |
| QSI | Quantum-Si Incorporated | $1,691,614 | -33.5% | 924,379 | 0.0% | 1.31% | -32.8% | |
| PHVS | Pharvaris N.V. | $384,098 | +46.6% | 34,142 | 0.0% | 0.30% | +48.3% | |
| ME | Exit | 23andMe Holding Co. | $0 | – | -406,913 | -100.0% | -0.90% | – |
| ENTA | Exit | Enanta Pharmaceuticals, Inc. | $0 | – | -42,250 | -100.0% | -1.68% | – |
| GMTX | Exit | Gemini Therapeutics, Inc. | $0 | – | -2,435,125 | -100.0% | -3.07% | – |
| Exit | Invivyd, Inc. | $0 | – | -1,431,826 | -100.0% | -3.45% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Kinnate Biopharma Inc. | 12 | Q3 2023 | 25.8% |
| Hims & Hers Health, Inc. | 11 | Q3 2023 | 37.5% |
| Aclaris Therapeutics, Inc. | 11 | Q3 2023 | 15.4% |
| Pharvaris N.V. | 11 | Q3 2023 | 5.5% |
| Quantum-Si Incorporated | 9 | Q2 2023 | 11.3% |
| TheseusPharmaceuticals, Inc. | 8 | Q3 2023 | 24.4% |
| Somalogic, Inc. | 8 | Q2 2023 | 20.5% |
| Compass Therapeutics, Inc. | 8 | Q3 2023 | 17.2% |
| Pardes Biosciences Inc | 7 | Q2 2023 | 37.8% |
| Gemini Therapeutics, Inc. | 7 | Q3 2022 | 9.7% |
View Foresite Capital Management V, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-05 |
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-13 |
| 4 | 2023-08-31 |
| 13F-HR | 2023-08-11 |
| 4 | 2023-07-19 |
| 13F-HR | 2023-05-12 |
| 4 | 2023-05-10 |
| 4 | 2023-04-06 |
| 4 | 2023-02-22 |
View Foresite Capital Management V, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.